Monday.Com에 대한 매도 수량은 투자자에게 Monday.Com의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Monday.Com (NASDAQ:MNDY) 주식, 공매도 수량 보고

Monday.Com

Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.

Intel’s Struggles Deepen

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ABNB

BABA

BROS

DKNG

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INTC

MNDY

SMCI

이들 12개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 힘스 앤 허스 헬스(NYSE:HIMS)의 주식은 지난주 42.12% 상승했다. 이는 슈퍼볼 광고 이후의 모멘텀에 힘입어 상승한 것으로 보인다.

슈퍼 마이크로, 인텔, 알리바바 및 CVS 등 지난주 상승한 12개 대형주 (2월 10일-2월 14일)

5 Stocks To Watch Heading Into Tuesday

Markets

$BTC

TSLA

월요일(10일) 미국 증시는 나스닥 종합지수가 약 1% 상승한 19,714.27포인트를 기록하는 등 긍정적인 분위기였다. S&amp;P 500 지수도 0.7% 상승한 6,066.44포인트를 기록했고, 다우존스 산업평균지수는 0.4% 상승한 44,470.41포인트를 기록했다.
월요일에 소매 투자자들과 트레이더의 주목을 받은 주요 주식은 다음과 같다.

월요일 주목받은 주식: 슈퍼마이크로컴퓨터, 게임스탑, 맥도날드, 먼데이닷컴 및 테슬라

arm-qualcomm-shutter

CTAS

CVNA

MSTR

PAYC

QCOM

VRTX

이들 11개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 노보 노디스크 A/S(NYSE:NVO)의 주식이 20.52% 하락했다. 이는 회사가 REDEFINE 1의 3상 시험 주요 결과를 발표한 후 발생한 일이다.

노보 노디스크, 버텍스 및 Arm은 지난주 최악의 성과를 보인 11개 대형주 중 일부 (12월 16-20일)

Monday.Com Ltd

Including this latest order, bookings for products from this OEM of natural gas turbines exceed $2.0 million in the first quarter of 2025.

Contracts

BWEN

Broadwind Secures Strategic Order For Precision Components Supporting Power Generation

In the last three months, 6 analysts have published ratings on Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $300.33, a high estimate of $339.00, and a low estimate of $252.00. This current average has decreased by 8.9% from the previous average price target of $329.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631293_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Evercore by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$252.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$281.00</td>
<td>$321.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$306.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$339.00</td>
<td>$319.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$305.00</td>
<td>$318.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$319.00</td>
<td>$339.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evercore. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Evercore compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Evercore's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Evercore's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EVR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evercore analyst ratings.</a>
<h2>Unveiling the Story Behind Evercore</h2>
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,380 employees at the end of 2024, and about 75% of its revenue is derived from the United States.
<h3>Financial Insights: Evercore</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Evercore's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 24.38% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Evercore's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Evercore's ROE excels beyond industry benchmarks, reaching 8.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Evercore's ROA excels beyond industry benchmarks, reaching 3.63%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.54, Evercore adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Evercore: 6 Analysts Share Their Views

In the last three months, 7 analysts have published ratings on Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Wolfspeed, revealing an average target of $10.43, a high estimate of $17.00, and a low estimate of $6.00. A 32.1% drop is evident in the current average compared to the previous average price target of $15.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631282_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Wolfspeed among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Wolfspeed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Wolfspeed compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Wolfspeed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Wolfspeed's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WOLF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Wolfspeed analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Wolfspeed: A Closer Look</h2>
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
<h3>Understanding the Numbers: Wolfspeed's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Wolfspeed faced challenges, resulting in a decline of approximately -13.39% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Wolfspeed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -206.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Wolfspeed's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -74.33%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Wolfspeed's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.77%, the company showcases efficient use of assets and strong financial health.
Debt Management: Wolfspeed's debt-to-equity ratio stands notably higher than the industry average, reaching 12.01. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WOLF

Wolfspeed Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Throughout the last three months, 4 analysts have evaluated Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.79, a high estimate of $14.00, and a low estimate of $1.15. A decline of 4.6% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631272_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gevo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.15</td>
<td>$3.25</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gevo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gevo compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gevo's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gevo's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gevo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Gevo Better</h2>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
<h3>Key Indicators: Gevo's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Gevo displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 30.32%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Gevo's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -308.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gevo's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Gevo's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GEVO

Expert Outlook: Gevo Through The Eyes Of 4 Analysts

In the latest quarter, 8 analysts provided ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $276.0, with a high estimate of $300.00 and a low estimate of $260.00. This current average has increased by 5.11% from the previous average price target of $262.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631264_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Labcorp Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Labcorp Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Get to Know Labcorp Hldgs Better</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Hldgs showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Hldgs's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Assessing Labcorp Hldgs: Insights From 8 Financial Analysts

Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $126.67, along with a high estimate of $132.00 and a low estimate of $100.00. This current average has increased by 7.65% from the previous average price target of $117.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631256_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Intra-Cellular Therapies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Intra-Cellular Therapies: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 51.49%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -8.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.47%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITCI

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 20.0% on an annualized basis producing an average annual return of 36.31%. Currently, Canadian Natural Res has a market capitalization of $64.64 billion. 
Buying $1000 In CNQ: If an investor had bought $1000 of CNQ stock 5 years ago, it would be worth $4,657.78 today based on a price of $30.79 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743631248_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

11 analysts have shared their evaluations of BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1135.91, with a high estimate of $1275.00 and a low estimate of $971.00. Witnessing a positive shift, the current average has risen by 0.84% from the previous average price target of $1126.45.
<img src="https://www.benzinga.com/files/images/story/2025/1743631248_0_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of BlackRock's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1046.00</td>
<td>$1053.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1045.00</td>
<td>$1017.00</td>
</tr>
<tr>
<td>Mike Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1275.00</td>
<td>$1261.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1180.00</td>
<td>$1160.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1175.00</td>
<td>$1155.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1053.00</td>
<td>$971.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$1275.00</td>
<td>$1215.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$971.00</td>
<td>$914.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1160.00</td>
<td>$1225.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1160.00</td>
<td>$1220.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1155.00</td>
<td>$1200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BlackRock. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of BlackRock compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of BlackRock's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BlackRock's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BLK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BlackRock analyst ratings.</a>
<h2>Unveiling the Story Behind BlackRock</h2>
BlackRock is the largest asset manager in the world, with $11.475 trillion in assets under management at the end of September 2024. Its product mix is fairly diverse, with 55% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 3% in alternatives. Passive strategies account for around two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.
<h3>BlackRock's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: BlackRock displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 22.59%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: BlackRock's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 29.42%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BlackRock's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.77%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): BlackRock's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: BlackRock's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down BlackRock: 11 Analysts Share Their Views

In the current session, the stock is trading at $236.32, after a 3.00% increase. Over the past month, Applied Industrial Techs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) stock increased by 1.52%, and in the past year, by 21.65%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1743631217_0.png" alt="Past Year Chart" />

<h3>How Does Applied Industrial Techs P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Applied Industrial Techs has a better P/E ratio of 23.22 than the aggregate P/E ratio of 21.21 of the Trading Companies &amp; Distributors industry. Ideally, one might believe that Applied Industrial Techs Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743631217_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Applied Industrial Techs

WMPN

Mid Penn Bancorp, William Penn Bancorporation Secure Shareholder Approvals For Merger

Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) has outperformed the market over the past 20 years by 1.41% on an annualized basis producing an average annual return of 9.55%. Currently, Vail Resorts has a market capitalization of $6.06 billion. 
Buying $100 In MTN: If an investor had bought $100 of MTN stock 20 years ago, it would be worth $619.11 today based on a price of $162.33 for MTN at the time of writing.
<h3>Vail Resorts's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743630327_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vail Resorts Stock In The Last 20 Years

A sweeping new wave of tariffs unveiled by President Donald Trump on Wednesday triggered a sharp selloff during the after hours of trading as the scope and scale of the trade duties exceeded <a href="https://www.benzinga.com/25/04/44616760/donald-trump-sets-reciprocal-tariffs-on-key-trade-partners-in-historic-policy-shock">Wall Street's worst-case expectations.</a>
The president framed the move as a long-overdue correction to decades of trade imbalance, instituting what he called a "reciprocal tariff rate," set at 50% of what trading partners charge the United States, but also factoring in non-tariff barriers like currency manipulation, value-added taxes and outright import bans.
While Trump had telegraphed his intention to "rebalance" U.S. trade policy, the specific duty levels, some of which reached into the mid-30% range with key trading partners, jolted investors.
Under the new framework, China, which Trump said imposes tariffs as high as 67% on American goods, will now face reciprocal U.S. duties of approximately 37%. The European Union, which applies a 39% combined rate including VATs, will be subject to a 20% U.S. tariff. Japan, with an estimated 46% trade barrier, now faces a 24% duty on exports to the U.S.
Canada and Mexico, two major trading partners, were notably excluded from the tariff program — a move that suggests Trump may be preserving the U.S.-Mexico-Canada Agreement, at least for now.
The White House confirmed that new trade tariffs will take effect on April 9. 
<h3 class="wp-block-heading">Tariffs Spark After-Hours Chaos: Index Futures Dive</h3>
The market&#8217;s reaction was swift and brutal. By 5:10 p.m. ET, futures on the S&amp;P 500 dropped 2.5%, while Nasdaq 100 futures fell 3.3%. Dow Jones Industrial Average contracts lost 1.4% and the Russell 2000 futures collapsed by 4.7%. 
Losses were broad-based. Every major sector of the S&amp;P 500 was in the red, with Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) and Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) down about 3%.
As risk appetite evaporated, gold prices climbed. Futures on the yellow metal gained 1.1%, extending their year-to-date advance as investors sought shelter from escalating geopolitical and trade tensions.
<h3 class="wp-block-heading">Tech Megacaps Bear the Brunt</h3>
The Magnificent Seven stocks, the market's dominant tech names, are on track to lose a combined $685 billion.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was the biggest laggard, down 6.6% and projected to erase $221.7 billion in market value.
 Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) lost 4.7%, a drop equivalent to $127.2 billion. Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fell 5.1%, and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slid nearly 6%, as traders repositioned for a potentially more inflationary and protectionist economic environment.
Here's the breakdown of projected market cap losses with the tech elite group:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Market Cap ($B)</th>
<th>Post-Mkt % Chg</th>
<th>Projected Loss ($B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apple Inc.</td>
<td>3364.8</td>
<td>-6.59%</td>
<td>-221.7</td>
</tr>
<tr>
<td>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>2842.7</td>
<td>-1.99%</td>
<td>-56.6</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>2694.6</td>
<td>-4.72%</td>
<td>-127.2</td>
</tr>
<tr>
<td>Amazon.com, Inc. </td>
<td>2079.0</td>
<td>-5.06%</td>
<td>-105.2</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</td>
<td>1923.7</td>
<td>-3.09%</td>
<td>-59.4</td>
</tr>
<tr>
<td>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>1480.5</td>
<td>-4.16%</td>
<td>-61.6</td>
</tr>
<tr>
<td>Tesla, Inc. </td>
<td>910.7</td>
<td>-5.86%</td>
<td>-53.4</td>
</tr>
<tr>
<td>Total</td>
<td>—</td>
<td>—</td>
<td>-685.1</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data, the steepest decliners in the aftermarket session included:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>)</td>
<td>-24.41%</td>
</tr>
<tr>
<td>Penske Automotive Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>)</td>
<td>-22.47%</td>
</tr>
<tr>
<td>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)</td>
<td>-12.51%</td>
</tr>
<tr>
<td>Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>)</td>
<td>-11.61%</td>
</tr>
<tr>
<td>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>)</td>
<td>-11.60%</td>
</tr>
<tr>
<td>lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)</td>
<td>-10.82%</td>
</tr>
<tr>
<td>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)</td>
<td>-10.38%</td>
</tr>
</tbody>
</table>
</figure>
Major gainers were: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dillard&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>)</td>
<td>+4.36%</td>
</tr>
<tr>
<td>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>)</td>
<td>+4.16%</td>
</tr>
<tr>
<td>Federal Realty Investment Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>)</td>
<td>+3.78%</td>
</tr>
<tr>
<td>Reinsurance Group of America, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>)</td>
<td>+2.79%</td>
</tr>
<tr>
<td>Ferguson Enterprises Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NASDAQ">FERG</a>)</td>
<td>+2.57%</td>
</tr>
<tr>
<td>Church &amp; Dwight Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>)</td>
<td>+2.48%</td>
</tr>
<tr>
<td>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>)</td>
<td>+2.33%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44610548/trumps-auto-tariffs-could-crush-demand-blow-26-billion-hole-in-industry-profits">Trump&#8217;s Auto Tariffs Could Crush Demand, Blow $26 Billion Hole In Industry Profits</a></li>
</ul>
Image created using photos from Shutterstock.

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Tech

ETFs

AMZN

CERT

FERG

FIVE

GOOGL

LULU

MSFT

NVDA

Select Sector SPDR-Consumer Discretionary

Markets Reel As Trump's Tariffs Hit — Magnificent 7 Set To Shed Almost $700 Billion

The Offering is expected to close on April 4, 2025, subject to customary closing conditions. The Notes will bear interest at the rate of 10.000% per year.&nbsp;
The Notes will mature on April 15, 2030 (subject to certain earlier maturity triggers). The Notes were offered at a price of 100% of their principal amount.

Offerings

Owens & Minor Reports Upsize And Pricing Of $1B Senior Secured Notes Offering

Shares of specialty retailers in the furniture and home goods space are facing selling pressure in Wednesday&#8217;s after-hours session following <a href="https://www.benzinga.com/news/earnings/25/04/44616824/rh-q4-earnings-shares-sink-as-revenue-eps-miss-expectations">disappointing earnings from RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>)</a>.
What To Know: RH missed analyst estimates on the top and bottom lines in the fourth quarter, reporting revenue of $812.41 million versus estimates of $829.56 million, and adjusted earnings of $1.58 per share versus estimates of $1.92 per share.
The company said demand softened in mid-December after mortgage rates spiked after the Federal Reserve signaled that rates would remain largely unchanged. The demand commentary appears to be weighing on shares of Wayfair Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) and Williams-Sonoma Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>), which are due to report quarterly results next month.
Wayfair considers itself &#8220;the destination for all things home.&#8221; The home furnishings retailer will report its first-quarter financial results before the market opens on May 1. Analysts currently expect the company to report a loss of 22 cents per share on revenue of $2.71 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Williams-Sonoma is a digital-first home retailer. The company is due to report first-quarter results sometime in May, although a date has not yet been confirmed. Analysts are looking for earnings of $1.74 per share and revenue of $1.65 billion, per <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates.
It&#8217;s also worth noting that broader markets are facing heavy selling pressure after hours after President Donald Trump announced reciprocal tariffs on a slew of countries at an event outside of the White House. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, was down about 2.27% after hours at last check.
W, WSM Price Action: At publication time, Wayfair shares were down 14% after-hours, trading at $29, and Williams-Sonoma shares were down 8.41% after-hours at $150.13, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/sheilasay">Sheila Say</a>/Shutterstock.

Earnings

After-Hours Center

Wayfair, Williams-Sonoma Shares Fall After The Bell: Here's Why

Getty Images and Shutterstock intend to continue working cooperatively with the DOJ and other non-US regulators to obtain regulatory clearance for the proposed merger as expeditiously as possible.
Both parties continue to expect the transaction to close in the second half of 2025.

GETY

SSTK

Getty Images, Shutterstock Receive Request For Additional Information And Documentary Material From US DoJ In Connection Proposed Merger

Shares of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reversed midday Wednesday, closing up 5%, after it was reported that CEO Elon Musk would <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44611347/is-elon-musk-leaving-doge-role-trump-tells-cabinet-move-could-happen-soon-report">step back from his prominent role</a> in the Trump Administration in the coming weeks.
At last check, shares were down over 3.2% in after-hours trading. 
What Happened: Politico <a href="https://www.politico.com/news/magazine/2025/04/02/trump-musk-leaving-political-liability-00265784">reported</a> that Trump told his cabinet that Musk could leave his administration soon. While Trump has publicly praised Musk&#8217;s actions leading the Department of Government Efficiency, political operatives and journalists believe Musk may be a liability to the administration.
For example, Musk reportedly invested over $20 million to defeat Democrat Susan Crawford in Tuesday&#8217;s Wisconsin Supreme Court election. 
Crawford won. 
Musk&#8217;s exit could also be due to his status as a special government employee, meaning he can only work 130 days each year. His position with the administration began in January.
The report was published midday on Wednesday; soon afterward, shares of Tesla rallied as investors—many of whom had wanted Musk to focus on the company he&#8217;s led since 2008 rather than politics—poured money into the carmaker.
Shares spiked over 6% in the hour following the report&#8217;s publication.
Musk, meanwhile, dismissed reports that he was leaving DOGE due to discord with other administration officials as &#8220;fake news.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yeah, fake news <a href="https://t.co/nPhTpZj3Fc">https://t.co/nPhTpZj3Fc</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1907519073287635313?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Tesla&#8217;s stock was the second-highest performing in the S&amp;P 500 between Trump&#8217;s election on Nov. 5, 2024, and his inauguration on Jan. 20, according to <a href="http://benzinga.com/pro">Benzinga Pro</a>. 
Investors&#8217; honeymoon was shortened when the company&#8217;s shares fell as much as 50% since Trump began his second term. Between Jan. 21 and March 21, Tesla was the second-worst-performing stock in the index.
The company experienced a <a href="https://www.benzinga.com/markets/equities/25/04/44601458/teslas-european-sales-decline-for-3rd-consecutive-month-amid-china-competition-ceo-elon-musks-political-controversies">decline in sales</a> in recent months, perhaps due to Musk&#8217;s <a href="https://www.benzinga.com/general/social-media/25/01/43219015/elon-musk-faces-criticism-from-biographer-over-auschwitz-visit-he-truly-is-a-sociopath">actions on inauguration day</a> and his <a href="https://www.benzinga.com/news/25/02/43914165/i-like-the-cars-its-musk-i-dont-like-former-elon-fan-dumps-both-teslas-and-cancels-cybertruck-order-to-boycott-elon-musk">polarizing political stature</a>. 
In particular, Tesla was hit particularly hard in European markets after Musk endorsed far-right parties in Germany and the United Kingdom.
It is unusual for executives to take on positions in presidential administrations while also leading their respective companies. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44612478/musk-needs-to-navigate-brand-crisis-or-else-warns-analyst-tesla-delivery-number-was-a-disaster-for-the-bulls">Musk Needs To &#8216;Navigate Brand Crisis Or Else,&#8221; Warns Analyst, Tesla &#8216;Delivery Number Was A Disaster For The Bulls&#8217;</a></li>
</ul>
Image: Shutterstock

Politics

Tesla Closes In Green, Dips After Hours As Musk Denies Ouster From Trump Administration

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) has outperformed the market over the past 5 years by 1.28% on an annualized basis producing an average annual return of 17.6%. Currently, Charles Schwab has a market capitalization of $140.21 billion. 
Buying $1000 In SCHW: If an investor had bought $1000 of SCHW stock 5 years ago, it would be worth $2,178.22 today based on a price of $77.31 for SCHW at the time of writing.
<h3>Charles Schwab's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743628530_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCHW

Here's How Much $1000 Invested In Charles Schwab 5 Years Ago Would Be Worth Today

<h3>Gainers</h3>
<ul>
<li>BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) shares increased by 13.5% to $2.6 during Wednesday's after-market session. The company's market cap stands at $184.6 million. </li>
<li>Euro Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) shares increased by 9.98% to $1.22. The market value of their outstanding shares is at $9.4 million. </li>
<li>Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) shares increased by 7.28% to $3.24. The market value of their outstanding shares is at $174.7 million. </li>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) stock moved upwards by 6.66% to $0.28. The market value of their outstanding shares is at $12.8 million. </li>
<li>Toppoint Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#AMEX">TOPP</a>) stock increased by 6.49% to $1.64. The market value of their outstanding shares is at $28.7 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares increased by 6.21% to $0.59. The company's market cap stands at $8.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares decreased by 14.9% to $23.73 during Wednesday's after-market session. The market value of their outstanding shares is at $313.1 million. As per the press release, Q2 earnings came out today. </li>
<li>Palladyne AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) stock fell 7.98% to $5.77. The company's market cap stands at $203.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLWT

PDYN

PITA

SLND

TOPP

8 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) shares rose 5.3% to $19.0 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out today. </li>
<li>Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) stock increased by 5.21% to $2.22. The market value of their outstanding shares is at $234.6 million. </li>
<li>Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) shares increased by 4.95% to $2.54. The company's market cap stands at $190.1 million. </li>
<li>Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) shares increased by 4.73% to $4.42. The market value of their outstanding shares is at $132.0 million. </li>
<li>Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) shares rose 4.56% to $8.7. The company's market cap stands at $393.6 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock moved upwards by 4.52% to $0.36. The company's market cap stands at $10.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) shares declined by 12.4% to $3.09 during Wednesday's after-market session. The market value of their outstanding shares is at $281.0 million. </li>
<li>PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) shares decreased by 9.73% to $16.53. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock decreased by 8.48% to $19.01. The company's market cap stands at $351.0 million. As per the press release, FY earnings came out 2 days ago. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock declined by 7.73% to $2.39. The market value of their outstanding shares is at $6.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMBM

CMCM

GRRR

IVDA

MITK

Penguin Solutions, Inc. - Ordinary Shares

Comments

Monday.Com

매도 수량

Monday.Com (NASDAQ:MNDY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌